Heterodimer compounds targeting nmda receptor-ca2+ channel, and preparation method and application thereof

By designing heterodimeric compounds of memantine hydrochloride and phenylalkylamine or dihydropyridine calcium antagonists, the problem of insufficient NMDA receptor and calcium ion channel inhibition in the treatment of vascular dementia by existing drugs has been solved, achieving more effective treatment results and higher blood-brain barrier permeability, and reducing the risk of drug use.

CN118271201BActive Publication Date: 2026-11-10HEFEI UNIV OF TECH
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202410376088.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-29
Publication Date
2026-11-10
Estimated Expiration
2044-03-29

AI Technical Summary

Technical Problem

Existing drugs have insufficient inhibitory effects on NMDA receptors and calcium ion channels when treating vascular dementia. Combined drug use brings metabolic burden and safety risks, and the low permeability of the blood-brain barrier affects the treatment effect.

Method used

A heterodimeric compound was designed by linking memantine hydrochloride with structural units of phenylalkylamine or dihydropyridine calcium antagonists to form a compound with dual functions of NMDA receptor and calcium ion channel, thereby enhancing blood-brain barrier permeability and facilitating preparation.

Benefits of technology

It improved the treatment effect of vascular dementia, reduced the dosage, lowered the metabolic burden and safety risks of long-term medication, and enhanced the brain-targeting effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118271201B_ABST
    Figure CN118271201B_ABST
Patent Text Reader

Abstract

This invention discloses a method using NMDA receptor-Ca 2+ Channel-targeted heterodimer compounds, their preparation methods, and applications, including NMDA receptor-Ca 2+ The structural formulas of channel heterodimers are represented by the following formulas (I-a), (I-b) and (II), (III): The heterodimer compounds of the present invention have multiple effects, including inhibiting NMDA receptors, reducing glutamate-induced NMDA receptor overexcitation and inhibiting calcium ion influx, inhibiting platelet aggregation, dilating blood vessels, and improving cognitive function. They also have high blood-brain barrier permeability and can be used for the prevention and treatment of vascular dementia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to drugs for vascular dementia and their preparation methods, specifically to a drug using NMDA receptor-Ca... 2+ Hybrid dimer compounds targeting channels, their preparation methods, and applications exhibit multiple effects, including inhibiting NMDA receptors and calcium ion channels, anti-platelet aggregation, vasodilation, improvement of learning and memory impairment, and high blood-brain barrier permeability. They can be applied to the prevention and treatment of vascular dementia. Background Technology

[0002] Vascular dementia (VD) is a neurodegenerative disease that can induce memory impairment, caused by cerebral vascular occlusion. The most important pathological outcome of vascular occlusion is cerebral ischemia, which occurs in discrete brain regions, leading to a significant reduction in cerebral blood flow (CBF). The pathogenesis and development of VD are the result of the interaction and accumulation of multiple pathogenic factors and pathological processes, and its course is a dynamic evolutionary process involving multiple targets, levels, and pathways. Its causes are mainly related to cerebrovascular diseases leading to cholinergic system disorders, decreased blood flow, neuronal apoptosis, neuroinflammation, and β-amyloid protein aggregation. These multiple factors ultimately cause cognitive dysfunction in patients. Clinically, N-methyl-D-aspartate (NMDA) receptor antagonists, calcium channel blockers, and other drugs are often used in combination to improve cognitive function, increase cerebral blood flow, and protect neurons, but the therapeutic effect needs further improvement.

[0003] Memantine hydrochloride is an ionotropic glutamate receptor antagonist that can effectively protect the nervous system, improve memory, and reduce cognitive impairment (Shao Li, Qin Jingcui, He Qing, et al. Effect of memantine combined with nimodipine in the treatment of non-dementia vascular cognitive impairment [J]. Guangdong Medical Journal, 2018, 39(24):3697-3700).

[0004] Memantine hydrochloride is an N-methyl-D-aspartate (NMDA) receptor antagonist. It is non-competitive, reversible, and exhibits certain affinity and voltage dependence. Memantine hydrochloride can effectively block pathological calcium ions (Ca) in neurons. 2+Overload antagonizes excessive excitation of glutamate receptors, preventing and inhibiting neuronal damage in patients, making it the first-line drug for vascular dementia. (Yao Mingrong, Fei Yu'e, Pu Zhengping, et al. Clinical observation of memantine hydrochloride in the treatment of vascular dementia patients [J]. Journal of Clinical Psychiatry, 2015, 25(4):271-272.). Studies have shown that memantine hydrochloride is also effective for patients with mild to moderate Alzheimer's disease. Common adverse reactions of memantine hydrochloride include drug allergy, drowsiness, dizziness, balance disorder, hypertension, dyspnea, and constipation. In addition, some patients may experience less common adverse reactions such as muscle spasms, tremors, tachycardia, and elevated blood pressure.

[0005] Verapamil (also known as IsoPtin, isopradoxime, or isopradoxime), chemically classified as a phenylalkylamine calcium channel blocker, was the world's first calcium channel blocker, developed in 1963 by the German company Knoll, and marketed under the name IsoPtin. Its hydrochloride salt is commonly used clinically and remains a first-line treatment for hypertension. It is also frequently used to treat angina and arrhythmias. Years of experimental research have demonstrated that not only does the amine component of verapamil, 3,4-dimethoxyphenylethylamine, possess cardiovascular activity, but N-substituted phenoxyacetylene 3,4-dimethoxyphenylethylamine also exhibits activity similar to alpha-receptor blockers. Based on this, it is speculated that 3,4-dimethoxyphenylethylamine may be the main component responsible for the efficacy of verapamil (Huang Wei. Process Improvement of Verapamil Hydrochloride and Design and Synthesis of its Derivatives [D]. Sichuan: Sichuan University, 2007.).

[0006] Amlodipine is a long-acting dihydropyridine calcium channel blocker, mainly used for the treatment of hypertension, coronary heart disease, angina pectoris, and heart failure. A study by Ye Qiufang et al. explored the effects of amlodipine on learning and memory from behavioral and pathological perspectives. The results showed that amlodipine could improve relevant indicators in the water maze behavioral test of VD rats and significantly alleviate the pathological changes in VD caused by bilateral common carotid artery blockage, suggesting that long-term use of amlodipine may improve learning in VD rats (Ye Qiufang, Xie Xianglin, Zou Hongbin, et al. Effects of amlodipine on learning and memory in vascular dementia rats [J]. Chinese Journal of Gerontology).

[0007] Zhi, 2011, 31(02):295-297.).

[0008] By binding the major pharmacophores of memantine hydrochloride and calcium channel blockers to a specific site, it is expected to have a dual effect of inhibiting NMDA receptors and calcium ion channels. This approach has the advantages of high blood-brain barrier penetration and easy preparation, reducing the metabolic burden and safety issues of combined drug use, and aims to achieve a synergistic effect. Summary of the Invention

[0009] This invention aims to provide an NMDA receptor-Ca 2+ Channel-targeting heterodimer compounds, their preparation methods, and applications. The technical problem to be solved is to select suitable molecular structures that possess superior NMDA receptor and calcium ion channel inhibition effects and the ability to improve learning and memory impairment, while also having high blood-brain barrier penetration and being easy to prepare.

[0010] The heterodimeric compounds of this invention are based on the structural units of memantine hydrochloride and phenylalkylamine or dihydropyridine calcium antagonist drugs as the parent core, and their structures are selected from compounds shown in formulas (Ia) and (Ib):

[0011]

[0012]

[0013] The method for preparing the heterodimer compound of the present invention includes a two-step amide condensation reaction and post-processing steps:

[0014] Step 1: First step amide condensation reaction

[0015] The diacid was dissolved in a round-bottom flask containing tetrahydrofuran, stirred at 0°C for 3-5 min, and triethylamine was added. Then, ethyl chloroformate was added dropwise, followed by the slow addition of memantine hydrochloride. The reaction was carried out in an ice bath for 2 h. After the reaction was completed, the solvent was removed by vacuum distillation, dissolved in sodium hydroxide solution and filtered. The pH of the filtrate was adjusted to about 6, filtered and dried to obtain the crude product. Intermediate A was obtained by silica gel column chromatography.

[0016] The structure of the diacid is shown below:

[0017]

[0018] Where n = 3 to 8;

[0019] The structure of intermediate A is shown below:

[0020]

[0021] Where n = 3 to 8;

[0022] Step 2: Second step amide condensation reaction

[0023] Intermediate A was placed in a round-bottom flask containing solvent, and triethylamine, EDCI, HOBT, and 3,4-dimethoxyphenethylamine or amlodipine were added sequentially. The mixture was stirred at room temperature for 2-3 hours. After the reaction was completed, the solvent was removed by vacuum distillation, the product was washed with water, extracted with chloroform, dried with anhydrous magnesium sulfate, and purified by silica gel column chromatography to obtain the target product (Ia) or (Ib).

[0024] In the first step of the amide condensation reaction, the molar ratio of memantine hydrochloride to diacid is 1:1-1.5, such as 1:1, 1:1.2, or 1:1.5; among these, the reaction is most effective when the molar ratio is 1:1.5.

[0025] In the second step of the amide condensation reaction, the molar ratio of intermediate A to 3,4-dimethoxyphenethylamine or amlodipine is 1:1-1.5; among them, the reaction effect is best when the molar ratio is 1:1.5.

[0026] In the second step of the amide condensation reaction, the solvent is selected from one or more of acetonitrile, ethanol, tetrahydrofuran, acetone, and dichloromethane, with tetrahydrofuran being the most effective.

[0027] In the second step of the amide condensation reaction, the eluent used for purification by silica gel column chromatography was methanol:dichloromethane = 1:5 (v / v).

[0028] The reaction route is shown below:

[0029]

[0030] The present invention also provides a second heterodimeric compound, which is a composition of memantine hydrochloride and an amlodipine derivative linked by an amide bond, and its general structural formula is represented by the following general formula (II):

[0031]

[0032] In this context, R1 and R2 independently represent -CH3 or -C2H5, and R3 represents -CH3.

[0033] The preparation method of the heterodimer compound shown in general formula (II) includes the following unit processes: substitution reaction and hydrolysis, amide condensation reaction, and post-processing:

[0034] Step 1: Substitution reaction

[0035] Memantine hydrochloride was dissolved in a round-bottom flask containing dichloromethane, and then methyl chloroformate and triethylamine were slowly added. The reaction was carried out at 0°C for 5 hours. After the reaction was completed, the solvent was evaporated, the mixture was washed with water, extracted with chloroform, dried with anhydrous magnesium sulfate, and purified by silica gel column chromatography to obtain intermediate B.

[0036] The structural formula of intermediate B is:

[0037]

[0038] Step 2: Hydrolysis and amide condensation reaction

[0039] Intermediate B was dissolved in a round-bottom flask containing methanol, potassium hydroxide was added, and the mixture was refluxed at 75°C for about 3 hours. The solvent was removed by vacuum distillation, and the product was dissolved in water and the pH was adjusted to about 6. After filtration, the product was dried to obtain a white solid. The obtained white solid was dissolved in tetrahydrofuran solution, and EDCI, HOBT, and amlodipine or an amlodipine derivative were added. The mixture was stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed by evaporation, the product was washed with water, extracted with chloroform, dried over anhydrous magnesium sulfate, and purified by silica gel column chromatography to obtain the target product (II).

[0040] The general structural formula of the amlodipine derivative is:

[0041]

[0042] In this context, R1 and R2 independently represent -CH3 or -C2H5, and R3 represents -CH3.

[0043] In the hydrolysis reaction, after dissolving in water, concentrated hydrochloric acid is used to adjust the pH, with pH 6 being the most effective setting.

[0044] In the amide condensation reaction, the molar ratio of the white solid hydrolysis product to amlodipine is 1:1-1.5, such as 1:1, 1:1.2, or 1:1.5; among them, the reaction effect is best when the molar ratio is 1:1.5.

[0045] The reaction route is shown below:

[0046]

[0047] The third heterodimeric compound provided by this invention is a composition of memantine hydrochloride and noramlodipine or its derivatives linked by an amide bond, and its general structural formula is represented by the following general formula (Ⅲ):

[0048]

[0049] Where R represents -CH3 or -C2H5.

[0050] The preparation method of the heterodimer compound shown in general formula (III) includes amide condensation reaction and post-processing steps:

[0051] The amide condensation reaction is carried out by placing memantine hydrochloride in a round-bottom flask containing dichloromethane, adding triethylamine, EDCI, DMAP, and desmethylamlodipine or its derivatives in sequence, stirring at room temperature for 2 hours, removing the solvent under reduced pressure after the reaction is complete, washing with water, extracting with chloroform, drying with anhydrous magnesium sulfate, and separating and purifying by silica gel column chromatography to obtain the target product (Ⅲ).

[0052] The structure of noramlodipine or its derivatives is shown below:

[0053]

[0054] Where R represents -CH3 or -C2H5.

[0055] In amide condensation reactions, the molar ratio of memantine hydrochloride to noramlodipine or its derivatives is 1:1-1.5, such as 1:1, 1:1.2, or 1:1.5; among these, the reaction is most effective when the molar ratio is 1:1.5.

[0056] The reaction route is shown below:

[0057]

[0058] This invention uses NMDA receptor-Ca 2+ Channel-targeted heterodimer compounds are used to prepare pharmaceutical formulations.

[0059] The drug formulation has both NMDA receptor and calcium ion channel inhibitory effects, improving cognitive and memory functions, thereby more effectively preventing and treating vascular dementia.

[0060] Compared with combination therapy, the drug formulation has increased blood-brain barrier permeability and better brain-targeting effect, which helps to reduce the dosage and reduce the metabolic burden and safety risks of long-term use.

[0061] This invention is based on the design of the NMDA receptor antagonist memantine hydrochloride and phenylalkylamine and dihydropyridine calcium channel inhibitors via suitable linkers. It possesses dual effects of NMDA receptor inhibition and calcium channel blockade, and has advantages such as high blood-brain barrier penetration and ease of preparation. The target product (Ib) has the effect of improving learning and memory impairment in VD rats and inhibiting hippocampal oxidative damage.

[0062] Compared with existing technologies, the beneficial effects of this invention are reflected in:

[0063] 1. Compared with existing drugs such as memantine hydrochloride, verapamil, and amlodipine, the present invention's NMDA receptor-Ca 2+ The channel derivatives retain the NMDA receptor inhibitory and calcium channel blocking effects of the two parent nuclei structures, thus more effectively preventing and treating vascular dementia.

[0064] 2. The NMDA receptor-Ca of this invention 2+ Compared with combination therapy, channel derivatives have prolonged plasma metabolism and increased blood-brain barrier permeability, resulting in good brain-targeting effects. This helps to reduce the dosage and decrease the metabolic burden and safety risks associated with long-term use. Detailed Implementation

[0065] Example 1: Synthesis of intermediate A1 — 6-(((1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)amino)-6-oxohexanoic acid

[0066]

[0067] 5 mmol of adipic acid was dissolved in tetrahydrofuran solution, stirred at 0℃ for 3-5 min, and 15 mmol of triethylamine was added. Then, 10 mmol of ethyl chloroformate was slowly added dropwise. After reacting for 5 min, 7.5 mmol of memantine hydrochloride was slowly added, and the reaction was carried out in an ice bath for 2 h. After the reaction was completed, the solvent was removed by vacuum distillation, dissolved in sodium hydroxide solution and filtered. The pH of the filtrate was adjusted to about 6 with concentrated hydrochloric acid, filtered and dried to obtain the crude product. The crude product was purified by silica gel column chromatography (eluent in a volume ratio of dichloromethane:methanol = 5:1) to obtain intermediate A1, with a yield of 65%.

[0068] 1 HNMR (600MHz, CDCl3) δ11.98(s,1H),7.25(s,1H),2.18(t,J=7.3Hz,2H),2.08–2.01(m,1H),1.97(t,J=7.3Hz, 2H),1.73(d,J=1.4Hz,2H),1.60–1.50(m,4H),1.48–1.40(m,4H),1.32–1.17(m,4H),1.08(s,2H),0.80(s,6H).

[0069] Example 2: Synthesis of Intermediate A2 — 8-(((1R,3R,5S,7R)-3,5-dimethyladamantane-1-yl)amino)-8-oxooctanoic acid

[0070]

[0071] The synthesis method is the same as in Example 1, except that glutaric acid in Example 1 is replaced with octanoic acid, and the yield is 62%.

[0072] 1 H NMR (600MHz, CDCl3) δ11.98(s,1H),7.23(s,1H),2.18(t,J=7.3Hz,2H),2.08–2.01(m,1H),1.97(t,J=7.3Hz,2 H),1.73(d,J=1.4Hz,2H),1.60–1.50(m,4H),1.49–1.37(m,4H),1.31–1.20(m,8H),1.08(s,2H),0.80(s,6H).

[0073] Example 3: Synthesis of intermediate A3 — 9-(((1R,3R,5S,7R)-3,5-dimethyladamantane-1-yl)amino)-9-oxononanoic acid

[0074]

[0075] The synthesis method is the same as in Example 1, except that glutaric acid in Example 1 is replaced with azelaic acid, and the yield is 60%.

[0076] 1 H NMR (600MHz, CDCl3) δ11.90(s,1H),7.23(s,1H),2.18(t,J=7.4Hz,2H),2.07–2.02(m,1H),1.97(t,J=7.3Hz,2 H),1.73(d,J=2.3Hz,2H),1.59–1.51(m,4H),1.50–1.39(m,4H),1.30–1.17(m,10H),1.08(s,2H),0.80(s,6H).

[0077] Example 4: Synthesis of intermediate A4 — 10-(((1R,3R,5S,7R)-3,5-dimethyladamantane-1-yl)amino)-10-oxodecanoic acid

[0078]

[0079] The synthesis method is the same as in Example 1, except that glutaric acid in Example 1 is replaced with sebacic acid, and the yield is 60%.

[0080] 1 H NMR (600MHz, CDCl3) δ11.90(s,1H),7.23(s,1H),2.18(t,J=7.3Hz,2H),2.07–2.02(m,1H),1.97(t,J=7.3Hz,2 H),1.73(d,J=2.3Hz,2H),1.59–1.51(m,4H),1.50–1.39(m,4H),1.31–1.16(m,12H),1.08(s,2H),0.80(s,6H).

[0081] Example 5: Synthesis of Intermediate B—((1R,3R,5S,7r)-3,5-dimethyladamantane-1-yl)carbamate

[0082]

[0083] 5 mmol of memantine hydrochloride was dissolved in a round-bottom flask containing dichloromethane. Then, 10 mmol of methyl chloroformate and 15 mmol of triethylamine were slowly added. The mixture was reacted at 0 °C for 5 h. After the reaction was completed, the solvent was evaporated, the mixture was washed with water, extracted with chloroform, dried over anhydrous magnesium sulfate, and purified by silica gel column chromatography (eluent: dichloromethane:methanol = 10:1, v / v) to obtain intermediate B in 65% yield.

[0084] 1 H NMR (600MHz, CDCl3) δ8.24(s,1H),3.79(s,3H),1.97(sept,J=2.8Hz,1H),1.84–1.68(m,6H),1.58–1.42(d,J=13.2Hz,6H),0.98–0.87(m,6H).

[0085] Example 6: Synthesis of target product C1—N1-(3,4-dimethoxyphenethyl)-N8-((1R,3R,5S,7R)-3,5-dimethyladamantane-1-yl)octadiamide

[0086]

[0087] 5 mmol of intermediate A2 was placed in a round-bottom flask containing tetrahydrofuran, and 15 mmol of triethylamine, 6 mmol of EDCI, 6 mmol of HOBT, and 7.5 mmol of 3,4-dimethoxyphenylethylamine were added sequentially. The mixture was stirred at room temperature for 2 h. After the reaction was complete, the solvent was removed by vacuum distillation, followed by washing with water, extraction with chloroform, drying with anhydrous magnesium sulfate, and purification by silica gel column chromatography (eluent: dichloromethane: methanol = 5:1, v / v) to obtain the target product C1.

[0088] Yellow solid, yield 58%, molecular formula C 30 H 46 N₂O₄, theoretical relative molecular mass 498.35, molecular ion peak m / z 497.3458 is [MH]. - .

[0089] 1H NMR (600MHz, CDCl3) δ8.13(s,1H),8.01(s,1H),6.80(d,J=7.5Hz,1H),6.76(q,J=1.1Hz,1H),6.72–6.64(m,1H),3.82(d,J=2.2Hz,8H),3.3 9(q,J=7.0Hz,3H),2.69(tt,J=7.1,1.1Hz,3H),2.30(td,J=7.1,4.9Hz,5H),2.09(d,J=12.5Hz,1H),1.99–1.78(m,13H),0.98–0.78(m,8H).

[0090] Example 7: Synthesis of target product C2—N1-(3,4-dimethoxyphenethyl)-N9-((1R,3R,5S,7R)-3,5-dimethyladamantane-1-yl)nonadiamide

[0091]

[0092] The synthesis process is the same as in Example 6, except that intermediate A2 in Example 6 is replaced with A3.

[0093] Yellow solid, yield 59%, molecular formula C 31 H 48 N₂O₄, theoretical relative molecular mass 512.36, molecular ion peak m / z 511.3614 [MH] - .

[0094] 1 H NMR (600MHz, CDCl3) δ8.13(s,1H),8.01(s,1H),6.80(d,J=7.5Hz,1H),6.76(q,J=1.1Hz,1H),6.72–6.64(m,1H),3.82(d,J=2.2Hz,8H),3.3 9(q,J=7.0Hz,3H),2.69(tt,J=7.1,1.1Hz,3H),2.30(td,J=7.1,4.9Hz,5H),2.09(d,J=12.5Hz,1H),1.97–1.77(m,15H),0.97–0.78(m,8H).

[0095] Example 8: Synthesis of target product C3 — 5-methyl-4-(2-chlorophenyl)-2-((2-(6-(1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)amino)-6-oxohexamido)ethoxy)methyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid ethyl ester

[0096]

[0097] The synthesis process is the same as in Example 6, except that intermediate A2 in Example 6 is replaced with A1.

[0098] White solid, yield 60%, molecular formula C 38 H 52 ClN3O7, theoretical relative molecular mass 697.35, molecular ion peak m / z 696.3494 [MH] - .

[0099] 1 H NMR(600MHz, CDCl3)δ8.80(s,1H),8.21(s,1H),8.05(s,1H),7.53–7.24(m, 4H),4.61(s,1H),4.34(s,2H),4.14(q,J=7.1Hz,2H),3.70(s,3H),3.53–3. 41(m,4H),2.50(s,3H),2.25–2.10(m,4H),1.98(sept,J=2.8Hz,1H),1.85– 1.67(m,6H),1.62–1.42(m,10H),1.20(t,J=7.1Hz,3H),0.98–0.88(m,6H).

[0100] Example 9: Synthesis of target product C4 — 5-methyl-4-(2-chlorophenyl)-2-((2-(10-(1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)amino)-10-oxodecanoamido)ethoxy)methyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid ethyl ester

[0101]

[0102] The synthesis process is the same as in Example 6, except that intermediate A2 in Example 6 is replaced with A4.

[0103] White solid, yield 58%, molecular formula C 38 H 52 ClN3O7, theoretical relative molecular mass 753.41, molecular ion peak m / z 752.4120 [MH] - .

[0104] 1H NMR(600MHz, CDCl3)δ8.80(s,1H),8.21(s,1H),8.05(s,1H),7.53–7.24(m,4H),4 .60(s,1H),4.35(s,2H),4.14(q,J=7.1Hz,2H),3.70(s,3H),3.63–3.47(m,4H),3 .31(t,J=7.2Hz,2H),2.50(s,3H),2.19(t,J=7.4Hz,2H),1.98(sept,J=2.8Hz,1H ),1.85–1.67(m,6H),1.66–1.42(m,10H),1.36–1.14(m,11H),0.98–0.88(m,6H).

[0105] Example 10: Synthesis of target product C5 — 4-(2-chlorophenyl)-2-((2-(3-((1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)ureo)ethoxy)methyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester

[0106]

[0107] 5 mmol of intermediate B was dissolved in a round-bottom flask containing methanol, and 15 mmol of potassium hydroxide was added. The mixture was refluxed at 75 °C for approximately 3 hours. The solvent was removed under reduced pressure, and the product was dissolved in water and the pH was adjusted to approximately 6. After filtration and drying, a white solid was obtained. This solid was dissolved in tetrahydrofuran solution, and 6 mmol of EDCI, 6 mmol of HOBT, and 7.5 mmol of amlodipine derivative 1 (i.e., dimethyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid) were added. The mixture was stirred at room temperature for 2 hours. After the reaction was completed, the solvent was removed, the product was washed with water, dried over anhydrous magnesium sulfate, and purified by silica gel column chromatography (eluent: dichloromethane:methanol = 5:1, v / v) to obtain the target product C5.

[0108] White solid, yield 30%, molecular formula C 32 H 42 ClN3O6, theoretical relative molecular mass 599.28, molecular ion peak m / z 598.2762 is [MH]. - .

[0109] 1H NMR(600MHz, CDCl3)δ8.80(s,1H),7.53–7.24(m,4H),6.49(s,1H),6.05(s,1H),4.61(s,1H),4.34(s,2H),3.76–3.65(m, 6H),3.56–3.42(m,4H),2.50(s,3H),1.98(sept,J=2.8Hz,1H),1.86–1.68(m,6H),1.58–1.42(m,6H),0.98–0.88(m,6H).

[0110] Example 11: Synthesis of target product C6—5-methyl-4-(2-chlorophenyl)-2-((2-(3-((1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)ureo)ethoxy)methyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid ethyl ester

[0111]

[0112] The synthesis process is the same as in Example 10, except that the amlodipine derivative in Example 10 is replaced with amlodipine.

[0113] White solid, yield 31%, molecular formula C2 33 H 44 ClN3O6, theoretical relative molecular mass 613.29, molecular ion peak m / z 612.2919 is [MH]. - .

[0114] 1H NMR(600MHz, CDCl3)δ8.80(s,1H),7.53–7.24(m,4H),6.49(s,1H),6.05(s,1H),4.61(s,1H),4.34(s,2H),4.14(q,J=7.1Hz,2H),3.70(s,3H ),3.56–3.42(m,4H),2.50(s,3H),1.98(sept,J=2.8Hz,1H),1.86–1.68(m,6H),1.58–1.42(m,6H),1.20(t,J=7.1Hz,3H),0.98–0.88(m,6H).

[0115] Example 12: Synthesis of target product C7 — 4-(2-chlorophenyl)-2-((2-(3-((1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)ureo)ethoxy)methyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester

[0116]

[0117] The synthesis process is the same as in Example 10, except that amlodipine derivative 1 in Example 10 is replaced with amlodipine derivative 2 (i.e., 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid diethyl ester).

[0118] White solid, yield 31%, molecular formula C2 34 H 46 ClN3O6, theoretical relative molecular mass 627.31, molecular ion peak m / z 626.3075 is [MH]. - .

[0119] 1 H NMR(600MHz, CDCl3)δ8.80(s,1H),7.53–7.24(m,4H),6.49(s,1H),6.05(s,1H),4.62(s,1H),4.34(s,2H),4.20–4.08(m,4H),3.56 –3.42(m,4H),2.50(s,3H),1.98(sept,J=2.8Hz,1H),1.86–1.68(m,6H),1.58–1.42(m,6H),1.28–1.14(m,6H),0.98–0.88(m,6H).

[0120] Example 13: Synthesis of target product C8—Ethyl 2-((2-aminoethoxy)methyl)-4-(2-chlorocyclohexyl-1,5-dien-1-yl)-5-(((1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)carbamoyl)-6-methyl-1,4-dihydropyridine-3-carboxylic acid ester

[0121]

[0122] 5 mmol of memantine hydrochloride was placed in a round-bottom flask containing dichloromethane, and 15 mmol of triethylamine, 6 mmol of EDCI, 6 mmol of HOBT, and 7.5 mmol of noramlodipine were added sequentially. The mixture was stirred at room temperature for 2 h. After the reaction was complete, the solvent was removed by vacuum distillation, followed by washing with water, extraction with chloroform, drying with anhydrous magnesium sulfate, and purification by silica gel column chromatography (eluent: dichloromethane:methanol = 5:1, v / v) to obtain the target product C8.

[0123] White solid, yield 32%, molecular formula C 31 H 44 ClN3O4, theoretical relative molecular mass 557.30, molecular ion peak m / z 556.3020 [MH] - .

[0124] 1 H NMR (600MHz, CDCl3) δ8.80 (s, 1H), 7.48 (s, 1H), 6.44 (d, J = 10.2Hz, 1H), 5.46 (ddd ,J=10.8,5.6,4.6Hz,1H),4.35(s,2H),4.22–4.08(m,3H),3.53(t,J=7.3Hz,2H), 2.86(t,J=7.3Hz,2H),2.70–2.45(m,5H),2.33(dddd,J=14.5,7.0,5.1,2.9Hz,2H ),2.04–1.70(m,9H),1.59–1.43(m,6H),1.20(t,J=7.1Hz,3H),0.98–0.88(m,6H).

[0125] Example 14: Synthesis of target product C9—2-((2-aminoethoxy)methyl)-4-(2-chlorocyclohexyl-1,5-dien-1-yl)-5-(((1r,3R,5S,7r)-3,5-dimethyladamantane-1-yl)carbamoyl)-6-methyl-1,4-dihydropyridine-3-carboxylic acid methyl ester

[0126]

[0127] The synthesis process is the same as in Example 13, except that desmeamlodipine in Example 13 is replaced with a desmeamlodipine derivative (i.e., 6-((2-aminoethoxy)methyl)-4-(2-chlorocyclohex-1,5-dien-1-yl)-5-methoxycarbonyl-2-methyl-1,4-dihydropyridine-3-carboxylic acid).

[0128] White solid, yield 33%, molecular formula C 30 H 42 ClN3O4, theoretical relative molecular mass 543.29, molecular ion peak m / z 542.2864 is [MH]. - .

[0129] 1H NMR (600MHz, CDCl3) δ8.80 (s, 1H), 7.48 (s, 1H), 6.44 (d, J = 10.2Hz, 1H), 5.46 ( ddd,J=10.8,5.6,4.6Hz,1H),4.35(s,2H),4.17(s,1H),3.71(s,3H),3.53(t, J=7.3Hz,2H),2.86(t,J=7.3Hz,2H),2.70–2.44(m,5H),2.33(dddd,J=14.5,7 .0,5.1,2.9Hz,2H),2.04–1.70(m,9H),1.59–1.43(m,6H),0.98–0.88(m,6H).

[0130] Example 15: Evaluation of in vitro NMDA receptor antagonistic activity

[0131] 1. Through in vitro [ 3 The H]MK-801 binding site assay was used to test the antagonistic activity of the target compound against the NMDA receptor. MK-801 is a selective, non-competitive NMDA receptor antagonist. A crude meningeal deposit was prepared by obtaining rat cerebral cortex containing NMDA receptors, and […]. 3 H]MK-801 was combined with meningeal deposits, and a certain concentration of the target compound was added. The mixture was incubated for a certain period of time, and then the free and bound radioligands were separated. The antagonistic activity of the compound against NMDA receptors was determined by measuring the change in the radioactivity count per minute (cpm value) of the bound radioligands compared with the cpm value without the compound.

[0132] 2. Results

[0133] Table 1. Study on the NMDA receptor inhibition rate of the compounds.

[0134]

[0135] The results in Table 1 show that compounds C1 and C4 have good NMDA receptor inhibitory activity, which is close to that of memantine hydrochloride, and can be further studied as candidate compounds.

[0136] Example 16: Evaluation of in vitro calcium antagonistic activity

[0137] 1. Assay for calcium antagonistic activity

[0138] Prepared rabbit aortic strips (3 mm wide, 20–30 mm long) were punctured and ligated, then placed in McBurney's bath tubes. One end was connected to the L-shaped tube of the water bath, and the other end was connected to a tension transducer. The water bath temperature was adjusted to 37°C. The McBurney's bath tube contained 30 ml of Kjeldahl solution, and a mixture of 95% oxygen and 5% carbon dioxide was introduced. The recorder was connected to the tension transducer, and after the aortic strips stabilized for approximately 1 hour, their normal tension curve was recorded. 0.2 mL of a 2% ethanol aqueous solution containing 100 μmol / L of the drug was added, and the tension curve was recorded after 15 minutes. The sample was then rinsed, and the process was repeated three times. The vasoconstriction inhibition rate was calculated based on the tension curves.

[0139] 2. Results Table 2: Study on the vasomotor inhibition rate of compounds

[0140]

[0141] The results showed that compounds C3 and C4 significantly inhibited vasoconstriction in isolated rabbit aortic strips, even more so than the calcium antagonists verapamil and amlodipine, indicating that compounds C3 and C4 possess certain calcium antagonistic activity. Considering both in vitro NMDA receptor antagonistic activity and calcium antagonistic activity evaluations, compounds C3 and C4 exhibited a well-balanced dual-target inhibitory effect, warranting further investigation into their blood-brain barrier permeability.

[0142] Example 17: Study on blood-brain barrier permeability of compounds C3 and C4

[0143] 1. Animal grouping, drug administration and treatment

[0144] Grouping: Sixty-eight healthy Kunming mice, weighing between 20±2g, half male and half female, were selected and housed in an SPF-grade barrier facility. Temperature: 20±2℃, air humidity: 45%-55%, pressure gradient: 20Pa-50 Pa, 12h / 12h free light cycle, with fewer than 4 mice per cage. The entire rearing process was strictly carried out and managed according to the standard operating procedures for barrier facilities.

[0145] The subjects were divided into four groups according to a randomized unit group design. Group A: Compound C3 administration group; Group B: Compound C4 administration group; Group C: Memantine hydrochloride group;

[0146] After the experiment began, mouse weight was recorded daily, approximately three times a week before and after drug administration. The mice were administered the drug via tail vein injection at a dose of 0.032 mmol / kg (equimolar dose for the control and experimental groups). At 10 min, 30 min, 90 min, 180 min, and 480 min after drug administration, plasma and brain tissue from each group were collected, weighed, and then homogenized with three times their weight of physiological saline. The homogenate was then frozen at -80°C for later use.

[0147] Accurately pipette 180 μL of plasma or brain homogenate, add 20 μL of internal standard solution, mix well, add 1 mL of methanol, vortex mix for 6 min for extraction, centrifuge at 4000 rpm for 12 min, take 2 μL of supernatant and inject into HPLC-MS, record the chromatogram and peak areas of the compound, memantine hydrochloride (As) and internal standard (Ai), and calculate the drug content in plasma and brain homogenate according to the linear equation.

[0148] Log BB represents the blood-brain barrier permeability of a drug. It is defined as the logarithm of the ratio of the drug concentration in the brain (ng / g) to the concentration in the blood (ng / mL) at steady-state distribution. The mathematical expression is:

[0149] Log BB = Log(C brain / C blood)

[0150] 2. Experimental Results

[0151] Table 3. Studies on the blood-brain barrier permeability of compounds.

[0152]

[0153] After mice were injected with memantine hydrochloride via the tail vein, the drug concentration detected in the brain homogenate was low. The Log BB was in steady state within 30-180 min after administration, with an average value of 0.016. For compounds C3 and C4, the Log BB was in relatively steady state within 30-480 min or 30-180 min after administration, with average values ​​of 0.253 and 0.263, respectively.

[0154] Table 3 shows that the ability to penetrate the blood-brain barrier was significantly improved after modification with amantadine derivatives. The steady-state log BB of compounds C3 and C4 was significantly higher than that of memantine hydrochloride. Compound C4 was rapidly transported into the brain from the bloodstream, and the brain drug concentration could be maintained for a relatively long time (the BB value was relatively stable at 180 min or 480 min), suggesting that it may have excellent blood-brain barrier penetration ability. Therefore, we conducted behavioral experiments on compound C4 in mice.

[0155] Example 18: Effects of compound C4 on learning and memory in VD rats

[0156] SD rats trained in a radial eight-arm maze for 7 days were randomly divided into a sham-operated group, a VD model group, a memantine hydrochloride administration group, and compound C4 administration groups (high, medium, and low doses). A VD rat model was established using bilateral common carotid artery permanent ligation. Neurological deficits were assessed using the Zea Longa et al. 5-point scoring system; a score ≥2 was considered a successful model. Compound C4 was administered at a dose of 2 mg / kg. -1 ·d -15mg·kg -1 ·d -1 10 mg·kg -1 ·d -1 The drug was administered at the prescribed dosage; the model control group and sham-operated group received only an equal volume of solvent. The medication was administered once daily via intraperitoneal injection for 21 consecutive days.

[0157] Following the initial training method, the eight-arm maze experiment was initiated at fixed times before drug administration from days 21 to 28. The experiment began on day 21, with training for the first 5 days and testing for the following 3 days. Working memory error (WME) was recorded for each rat re-entering the bait arm, while referencing memory error (RME) was recorded for entering the non-baited arm. WME and RME were recorded for each rat for each experiment within 10 minutes.

[0158] Table 4. Results of behavioral tests on VD rats using compound C4.

[0159]

[0160] *P<0.05 vs model group

[0161] Experimental results showed that, compared with the VD model group, compound C4 could effectively reduce the number of behavioral errors in rats.

Claims

1. A heterodimeric compound, characterized in that... Selected from compounds with the following structures: 。 2. The method for preparing the heterodimer compound according to claim 1, characterized in that... The synthesis route is shown below: ; 。 3. The use of the heterodimer compound of claim 1 in the preparation of pharmaceutical formulations, characterized in that: The pharmaceutical formulation uses the NMDA receptor-Ca 2+ The pathway is a target for drug formulations for the prevention and / or treatment of vascular dementia.

Citation Information

Patent Citations

  • Symmetrel derivatives and synthesis method thereof and their use as neuron damage protective agent

    CN1634859A

  • Therapeutic conjugates and methods of using same

    WO2007065036A2